138 related articles for article (PubMed ID: 30424755)
1. Expression and clinical significance of Caveolin-1 in prostate Cancer after transurethral surgery.
Wang X; Liu Z; Yang Z
BMC Urol; 2018 Nov; 18(1):102. PubMed ID: 30424755
[TBL] [Abstract][Full Text] [Related]
2. High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting.
Hammarsten P; Dahl Scherdin T; Hägglöf C; Andersson P; Wikström P; Stattin P; Egevad L; Granfors T; Bergh A
PLoS One; 2016; 11(10):e0164016. PubMed ID: 27764093
[TBL] [Abstract][Full Text] [Related]
3. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
4. Role of transurethral biopsy sampling of the prostate to diagnose prostate cancer in men undergoing surgical intervention for benign prostatic hyperplasia.
Bales GT; Flynn TJ; Kynaston HG; Golash A; Hart A; Kim HL; Gerber GS
Tech Urol; 2000 Sep; 6(3):201-4. PubMed ID: 10963487
[TBL] [Abstract][Full Text] [Related]
5. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
[TBL] [Abstract][Full Text] [Related]
6. Expression levels of heat shock protein 27 and cellular FLICE-like inhibitory protein in prostate cancer correlate with Gleason score sum and pathologic stage.
Lee SW; Cho JM; Cho HJ; Kang JY; Kim EK; Yoo TK
Korean J Urol; 2015 Jul; 56(7):505-14. PubMed ID: 26175869
[TBL] [Abstract][Full Text] [Related]
7. Caveolin-1 as a biomarker to predict therapeutic effect of low-frequency ultrasound combined with SonoVue on prostate cancer in nude mice model.
Xu W; Nan S; Bai W; Shen E; Hu B
Cancer Biomark; 2014; 14(4):279-86. PubMed ID: 24934371
[TBL] [Abstract][Full Text] [Related]
8. Changes in caveolae, caveolin, and polymerase 1 and transcript release factor (PTRF) expression in prostate cancer progression.
Gould ML; Williams G; Nicholson HD
Prostate; 2010 Nov; 70(15):1609-21. PubMed ID: 20564315
[TBL] [Abstract][Full Text] [Related]
9. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
10. [Prostatic cancer developing after transurethral resection of the prostate for benign prostatic hyperplasia].
Tanaka Y; Aoyama H; Momose H; Ono T; Samma S; Tanaka N; Akiyama T; Tani Y; Masuda Y; Matsuki H; Tani M; Tanaka M
Hinyokika Kiyo; 2001 Jan; 47(1):11-4. PubMed ID: 11235214
[TBL] [Abstract][Full Text] [Related]
11. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
[TBL] [Abstract][Full Text] [Related]
13. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
Karam JA; Lotan Y; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
Prostate; 2007 May; 67(6):614-22. PubMed ID: 17299799
[TBL] [Abstract][Full Text] [Related]
14. High Incidence of Incidental Prostate Cancer in Transurethral Resection of Prostate Specimens in China. The Value of Pathologic Review.
Lin J; Yu X; Yang X; Jin J; Zhou L; Liu L; Su J; Li Y; Shang M
Anal Quant Cytopathol Histpathol; 2016 Feb; 38(1):31-7. PubMed ID: 27363064
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of serum total and free prostate-specific antigen (PSA) after extended multisite prostate biopsy: Comparison among biopsy, transurethral resection of the prostate (TURP), and biopsy plus TURP.
Hara N; Koike H; Nobushita T; Miyajima N; Kawaguchi M; Nishiyama T; Takahashi K; Hohenfellner R
Urol Oncol; 2010; 28(4):355-9. PubMed ID: 19110451
[TBL] [Abstract][Full Text] [Related]
16. Transurethral prostatic resection for acute urinary retention in patients with prostate cancer.
Chang CC; Kuo JY; Chen KK; Lin AT; Chang YH; Wu HH; Chang LS
J Chin Med Assoc; 2006 Jan; 69(1):21-5. PubMed ID: 16447922
[TBL] [Abstract][Full Text] [Related]
17. Holmium laser enucleation versus transurethral resection of the prostate. Are histological findings comparable?
Naspro R; Freschi M; Salonia A; Guazzoni G; Girolamo V; Colombo R; Scattoni V; Rigatti P; Montorsi F
J Urol; 2004 Mar; 171(3):1203-6. PubMed ID: 14767301
[TBL] [Abstract][Full Text] [Related]
18. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era.
Jones JS; Follis HW; Johnson JR
Prostate Cancer Prostatic Dis; 2009; 12(1):57-60. PubMed ID: 18379587
[TBL] [Abstract][Full Text] [Related]
19. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
20. [Incidence and pathological features of incidental prostate cancer and clinical significance thereof].
Yang XY; Xia TL; He Q; Li W; Wang JH; Su JW; Li J; Na YQ
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(37):2632-4. PubMed ID: 18162152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
